273 related articles for article (PubMed ID: 23894374)
1. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
Wells CE; Bhaskara S; Stengel KR; Zhao Y; Sirbu B; Chagot B; Cortez D; Khabele D; Chazin WJ; Cooper A; Jacques V; Rusche J; Eischen CM; McGirt LY; Hiebert SW
PLoS One; 2013; 8(7):e68915. PubMed ID: 23894374
[TBL] [Abstract][Full Text] [Related]
2. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis.
Nihal M; Ahmad N; Wood GS
Cell Cycle; 2014; 13(4):632-40. PubMed ID: 24343700
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
4. Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy.
Stengel KR; Hiebert SW
Antioxid Redox Signal; 2015 Jul; 23(1):51-65. PubMed ID: 24730655
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage.
Conti C; Leo E; Eichler GS; Sordet O; Martin MM; Fan A; Aladjem MI; Pommier Y
Cancer Res; 2010 Jun; 70(11):4470-80. PubMed ID: 20460513
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.
Namdar M; Perez G; Ngo L; Marks PA
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20003-8. PubMed ID: 21037108
[TBL] [Abstract][Full Text] [Related]
7. HDAC inhibitor-based therapies: can we interpret the code?
New M; Olzscha H; La Thangue NB
Mol Oncol; 2012 Dec; 6(6):637-56. PubMed ID: 23141799
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Umamaheswari A; Puratchikody A; Hari N
Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
[TBL] [Abstract][Full Text] [Related]
9. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
10. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response.
Long J; Fang WY; Chang L; Gao WH; Shen Y; Jia MY; Zhang YX; Wang Y; Dou HB; Zhang WJ; Zhu J; Liang AB; Li JM; Hu J
Leukemia; 2017 Dec; 31(12):2761-2770. PubMed ID: 28462918
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells.
Borutinskaite VV; Magnusson KE; Navakauskiene R
Mol Biol Rep; 2012 Dec; 39(12):10179-86. PubMed ID: 23007576
[TBL] [Abstract][Full Text] [Related]
12. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
13. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
Chen J; Fiskus W; Eaton K; Fernandez P; Wang Y; Rao R; Lee P; Joshi R; Yang Y; Kolhe R; Balusu R; Chappa P; Natarajan K; Jillella A; Atadja P; Bhalla KN
Blood; 2009 Apr; 113(17):4038-48. PubMed ID: 19074726
[TBL] [Abstract][Full Text] [Related]
14. A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).
Harrison SJ; Bishton M; Bates SE; Grant S; Piekarz RL; Johnstone RW; Dai Y; Lee B; Araujo ME; Prince HM
Epigenomics; 2012 Oct; 4(5):571-89. PubMed ID: 23130838
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP
Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801
[TBL] [Abstract][Full Text] [Related]
17. HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.
Rajendran P; Kidane AI; Yu TW; Dashwood WM; Bisson WH; Löhr CV; Ho E; Williams DE; Dashwood RH
Epigenetics; 2013 Jun; 8(6):612-23. PubMed ID: 23770684
[TBL] [Abstract][Full Text] [Related]
18. BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.
Fu W; Yi S; Qiu L; Sun J; Tu P; Wang Y
J Invest Dermatol; 2017 Jul; 137(7):1523-1532. PubMed ID: 28288848
[TBL] [Abstract][Full Text] [Related]
19. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
Thurn KT; Thomas S; Moore A; Munster PN
Future Oncol; 2011 Feb; 7(2):263-83. PubMed ID: 21345145
[TBL] [Abstract][Full Text] [Related]
20. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]